Disease-Vaccine-Landing-Page/Meningitis/vaccine-effectiveness

In October 2023, the FDA approved use of PENBRAYA, a pentavalent meningococcal vaccine targeting the A, B, C, W, and Y meningococcal serogroups. According to the vaccine’s package insert, the...

Meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. Meningococcal serogroup B strains, however, are...

MenQuadfi received FDA approval 2020 based on clinical trials that reported the vaccine was not inferior in safety or immunogenicity when compared with Menomune, Menactra, and Menveo conjugate vaccines. ...

Approved by the FDA in 2010, Menveo (serogroups A, C, Y, and W-135) conjugate vaccine approval was based on safety and immunogenicity studies reporting the vaccine to be non-inferior to...

Clinical trials on Menactra’s (MCV4 or MenACWY-D) efficacy were not a requirement when FDA licensed its use in 2005. Menactra was the first meningococcal (serogroups A, C, Y, and W-135)...